Arcutis Biotherapeutics reported that director Howard G. Welgus sold 10,000 shares of the companys common stock on February 2, 2026, bringing in approximately $250,483. The shares changed hands at prices between $24.61 and $25.60 per share.
Following that disposition, Welgus's direct stake in Arcutis stands at 59,744 shares. The sale was carried out under a pre-arranged trading arrangement - a 10b5-1 plan - which Welgus adopted on March 11, 2025. That plan is scheduled to remain in effect through May 29, 2026.
These insider transactions come as the company communicates a series of operational and regulatory updates. Arcutis said results from its Phase 2 INTEGUMENT-INFANT study of ZORYVE cream were positive, with 58% of infants treated showing a 75% improvement in their atopic dermatitis after four weeks of therapy.
In a separate commercial change, Arcutis and Kowa Pharmaceuticals America have mutually agreed to end their promotion agreement for ZORYVE. Arcutis will assume responsibility for sales activities directly going forward.
The company also announced a leadership transition on its board: Amit Munshi has been appointed to the Board of Directors, taking the seat of founder Bhaskar Chaudhuri, who is retiring.
On the analyst front, Mizuho has raised its price target for Arcutis to $37.00 and continues to carry an Outperform rating, citing ZORYVE sales that exceeded expectations. Separately, the U.S. Food and Drug Administration has accepted Arcutis's application seeking to expand its psoriasis treatment to younger pediatric patients; the agency's decision is expected by June 29, 2026.
Taken together, the insider sale, the clinical readout, the commercial reorganization, the board succession and the regulatorily material filing form the sequence of recent disclosures from Arcutis Biotherapeutics. Each item was explicitly noted by the company in its public reporting.